HIF-PH-Inhibitoren in der Therapie der renalen Anämie

ZUSAMMENFASSUNG

Die bisherige Standardbehandlung der renalen Anämie umfasst die Sicherstellung ausreichender Eisenspeicher und die Verabreichung von Erythropoetin-Stimulanzien (ESA). Eine medikamentöse Alternative zu ESA sind nun Wirkstoffe, die HIF-PH (HIF: Hypoxie induzierbarer Faktor; PH: Prolylhydroxylasen) inhibieren. Denn Prolylhydroxylasen vermitteln den sauerstoffabhängigen Abbau von HIF und regulieren so die zelluläre Antwort auf Hypoxie in der Anämie und eine Reihe anderer chronischer Erkrankungen. HIF-PH-Inibitoren (HIF-PHI) sind eine neue Klasse oraler Medikamente, die HIF aktivieren und durch mehrere Mechanismen die Erythropoese steigern. HIF-PHI erhöhen nicht nur die Produktion von Erythropoetin und optimieren den Eisenmetabolismus, sondern besitzen durch die Vielzahl an HIF-regulierten Genen weitere zielgerichtete Wirkungen. Basierend auf den Daten zur Korrektur der renalen Anämie und zur Sicherheit bei dialysepflichtigen und nichtdialysepflichtigen Patienten mit chronischer Nierenerkrankung (CKD: „chronic kidney disease“) ist diese neue Wirkstoffklasse eine Alternative zu ESA. Die Europäische Arzneimittel-Agentur (EMA) hat Roxadustat im August 2021 für die klinische Anwendung in der Europäischen Union zugelassen.

Publication History

Article published online:
12 December 2022

• Literatur

• 1 Drüeke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 2012; 82: 952-960 DOI: 10.1038/ki.2012.270.
• 2 Bernhardt WM, Wiesener MS, Scigalla P. et al Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD. J Am Soc Nephrol 2010; 21: 2151-2156 DOI: 10.1681/ASN.2010010116.
• 3 Mikhail A, Brown C, Williams JA. et al Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 2017; 18: 345 DOI: 10.1186/s12882-017-0688-1.
• 4 Chronic kidney disease: managing anaemia | Guidance | NICE. Im Internet. https://www.nice.org.uk/guidance/ng8 Stand: 21.10.2022
• 5 Haase VH. Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl 2021; 11: 8-25 DOI: 10.1016/j.kisu.2020.12.002.
• 6 McMahon GM, Singh AK. Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens 2019; 28: 600-606 DOI: 10.1097/MNH.0000000000000554.
• 7 Evrenzo 20 mg/50 mg/70 mg/100 mg/150 mg Filmtabletten.
• 8 Böttcher M, Lentini S, Arens ER. et al First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. Br J Clin Pharmacol 2018; 84: 1557-1565 DOI: 10.1111/bcp.13584.
• 9 Groenendaal-van de Meent D, den Adel M, van Dijk J. et al Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects. Eur J Drug Metab Pharmacokinet 2018; 43: 685-692 DOI: 10.1007/s13318-018-0480-z.
• 10 Caltabiano S, Mahar KM, Lister K. et al The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects. Pharmacol Res Perspect 2018; 06: e00327 DOI: 10.1002/prp2.327.
• 11 Kurata Y, Tanaka T, Nangaku M. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens 2020; 29: 414-422 DOI: 10.1097/MNH.0000000000000617.
• 12 Natale P, Palmer SC, Jaure A. et al Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2022; 08: CD013751 DOI: 10.1002/14651858.CD013751.pub2.
• 13 Barratt J, Andric B, Tataradze A. et al Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant 2021; 36: 1616-1628 DOI: 10.1093/ndt/gfab191.
• 14 Provenzano R, Szczech L, Leong R. et al Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials. Clin J Am Soc Nephrol 2021; 16: 1190-1200 DOI: 10.2215/CJN.16191020.
• 15 Singh AK, Carroll K, McMurray JJV. et al Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med 2021; 385: 2313-2324 DOI: 10.1056/NEJMoa2113380.
• 16 Chertow GM, Pergola PE, Farag YMK. et al Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD. N Engl J Med 2021; 384: 1589-1600 DOI: 10.1056/NEJMoa2035938.
• 17 Barratt J, Sulowicz W, Schömig M. et al Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Adv Ther 2021; 38: 5345-5360 DOI: 10.1007/s12325-021-01903-7.
• 18 Singh AK, Carroll K, Perkovic V. et al Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med 2021; 385: 2325-2335 DOI: 10.1056/NEJMoa2113379.
• 19 Eckardt K-U, Agarwal R, Aswad A. et al Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med 2021; 384: 1601-1612 DOI: 10.1056/NEJMoa2025956.
• 20 Fishbane S, Pollock CA, El-Shahawy M. et al Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. J Am Soc Nephrol 2022; 33: 850-866 DOI: 10.1681/ASN.2020111638.
• 21 EMA. Evrenzo. Eur Med Agency 2021; Im Internet:. www.ema.europa.eu/en/medicines/human/EPAR/evrenzo Stand: 21.10.2022
• 22 FDA. Updated time information: July 15, 2021 Meeting of the Cardiovascular and Renal Drugs Advisory Committee Meeting Announcement. Im Internet. www.fda.gov/advisory-committees/advisory-committee-calendar/updated-time-information-july-15-2021-meeting-cardiovascular-and-renal-drugs-advisory-committee Stand: 21.10.2022
• 23 Besarab A, Bolton WK, Browne JK. et al The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin. N Engl J Med 1998; 339: 584-590 DOI: 10.1056/NEJM199808273390903.
• 24 Agarwal AK. Iron metabolism and management: focus on chronic kidney disease. Kidney Int Suppl 2021; 11: 46-58 DOI: 10.1016/j.kisu.2020.12.003.
• 25 Yap DYH, McMahon LP, Hao CM. et al Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrol Carlton Vic 2021; 26: 105-118 DOI: 10.1111/nep.13835.
• 26 Raichoudhury R, Spinowitz BS. Treatment of anemia in difficult-to-manage patients with chronic kidney disease. Kidney Int Suppl 2021; 11: 26-34 DOI: 10.1016/j.kisu.2020.12.006.
• 27 Locatelli F, Andrulli S, Memoli B. et al Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 991-998 DOI: 10.1093/ndt/gfk011.
• 28 Bárány P, Divino Filho JC, Bergström J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568 DOI: 10.1016/S0272-6386(97)90339-5.
• 29 Chen N, Hao C, Liu BC. et al Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. N Engl J Med 2019; 381: 1011-1022 DOI: 10.1056/NEJMoa1901713.
• 30 Liu Q, Davidoff O, Niss K. et al Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 2012; 122: 4635-4644 DOI: 10.1172/JCI63924.
• 31 Seeley TW, Sternlicht MD, Klaus SJ. et al Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia (Auckl) 2017; 05: 1-9 DOI: 10.2147/HP.S130526.
• 32 Pezzuto A, Carico E. Role of HIF-1 in Cancer Progression: Novel Insights. A Review. Curr Mol Med 2018; 18: 343-351 DOI: 10.2174/1566524018666181109121849.
• 33 Singh AK. et al Poster MO530. ERA-Kongress, 19.–22.05.2022
• 34 Pfeffer MA, Burdmann EA, Chen CY. et al A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med 2009; 361: 2019-2032 DOI: 10.1056/NEJMoa0907845.
• 35 Akizawa T, Iwasaki M, Yamaguchi Y. et al Authors’ Reply. J Am Soc Nephrol JASN. 2021 ASN.2021010051 DOI: 10.1681/ASN.2021010051